Abstract
X-ray computed tomography (CT), an efficient non-invasive clinical technique, usually provides highresolution 3D structure details of tissues in early disease diagnosis. Here, we report a high-performance CT imaging platform based on a monodispersed Yb-based nanoparticulate contrast agent. The well-prepared nanoprobes presented excellent in vitro and in vivo performances in the CT imaging, very low cytotoxicity and no detectable tissue damage in one month. More significantly, compared with routinely used Iobitridol in clinic, our Yb-based CT contrast agents provided much more enhanced contrast at a clinical 120 kVp voltage. Additionally, these nanoparticulate contrast agent could be excreted mainly via feces and urine, indicating the total elimination from the animal bodies and more potential for further biomedical applications.
Keywords: Yb-based nanoparticles, imaging agent, biocompatibility, large-scale synthesis, biomedicine.
Current Topics in Medicinal Chemistry
Title:Large-Scale and Facile Synthesis of Biocompatible Yb-Based Nanoparticles as a Contrast Agent for In Vivo X-Ray Computed Tomography Imaging
Volume: 13 Issue: 4
Author(s): Jianhua Liu, Rui Xin, Zhiman Li, Reza Golamaully, Yan Zhang, Jishen Zhang, Qinghai Yuan and Xiaodong Liu
Affiliation:
Keywords: Yb-based nanoparticles, imaging agent, biocompatibility, large-scale synthesis, biomedicine.
Abstract: X-ray computed tomography (CT), an efficient non-invasive clinical technique, usually provides highresolution 3D structure details of tissues in early disease diagnosis. Here, we report a high-performance CT imaging platform based on a monodispersed Yb-based nanoparticulate contrast agent. The well-prepared nanoprobes presented excellent in vitro and in vivo performances in the CT imaging, very low cytotoxicity and no detectable tissue damage in one month. More significantly, compared with routinely used Iobitridol in clinic, our Yb-based CT contrast agents provided much more enhanced contrast at a clinical 120 kVp voltage. Additionally, these nanoparticulate contrast agent could be excreted mainly via feces and urine, indicating the total elimination from the animal bodies and more potential for further biomedical applications.
Export Options
About this article
Cite this article as:
Liu Jianhua, Xin Rui, Li Zhiman, Golamaully Reza, Zhang Yan, Zhang Jishen, Yuan Qinghai and Liu Xiaodong, Large-Scale and Facile Synthesis of Biocompatible Yb-Based Nanoparticles as a Contrast Agent for In Vivo X-Ray Computed Tomography Imaging, Current Topics in Medicinal Chemistry 2013; 13 (4) . https://dx.doi.org/10.2174/1568026611313040011
DOI https://dx.doi.org/10.2174/1568026611313040011 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Betulinic Acid and Brosimine B Hybrid Derivatives as Potential Agents against Female Cancers
Anti-Cancer Agents in Medicinal Chemistry In Silico Design, Synthesis and Bioactivity of N-(2, 4-Dinitrophenyl)-3-oxo- 3-phenyl-N-(aryl) Phenyl Propanamide Derivatives as Breast Cancer Inhibitors
Current Computer-Aided Drug Design Proteasome Inhibitors in Cancer Therapy
Current Drug Targets Walking a Tightrope: A Perspective of Resveratrol Effects on Breast Cancer
Current Protein & Peptide Science DNA Damage Response Pathways and Cell Cycle Checkpoints in Colorectal Cancer: Current Concepts and Future Perspectives for Targeted Treatment
Current Cancer Drug Targets Strategies for Target-Specific Contrast Agents for Magnetic Resonance Imaging
Current Molecular Imaging (Discontinued) Mediterranean Diet, Brain and Muscle: Olive Polyphenols and Resveratrol Protection in Neurodegenerative and Neuromuscular Disorders
Current Medicinal Chemistry Targeting RGD Recognizing Integrins: Drug Development, Biomaterial Research, Tumor Imaging and Targeting
Current Pharmaceutical Design Pregnane X Receptor and its Potential Role in Drug Resistance in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Human Microdialysis
Current Pharmaceutical Biotechnology Epigenetics in Metastatic Breast Cancer: Its Regulation and Implications in Diagnosis, Prognosis and Therapeutics
Current Cancer Drug Targets Targeted Nanosystems for Cancer Therapy
Current Cancer Therapy Reviews Editorial [Hot topic:Food Addiction & Obesity Treatment Development (Executive Guest Editors: Mark S. Gold and Noni A. Graham)]
Current Pharmaceutical Design Polyphenols from Red Wine Modulate Immune Responsiveness: Biological and Clinical Significance
Current Pharmaceutical Design Novel Carbamοyloxy Analogues of Tamoxifen: Synthesis, Molecular Docking and Bioactivity Evaluation
Letters in Drug Design & Discovery Genetically Engineered Mouse Models for Drug Discovery: New Chemical Genetic Approaches
Current Drug Discovery Technologies PRL-3, An Emerging Marker of Carcinogenesis, Is Strongly Associated with Poor Prognosis
Anti-Cancer Agents in Medicinal Chemistry 4-Aryl-4H-Chromene-3-Carbonitrile Derivatives: Evaluation of Src Kinase Inhibitory and Anticancer Activities
Medicinal Chemistry Dithiocarbamate-based coordination compounds as potent proteasome inhibitors in human cancer cells
Mini-Reviews in Medicinal Chemistry Current Understanding of Dietary Polyphenols and their Role in Health and Disease
Current Nutrition & Food Science